Stocks Health care ETON
NASDAQ · Health careEton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc. brought in $141.1M of revenue over the twelve months to September 30, 2026, up 100.6% from a year earlier. Net income was $49.9M, a net margin of 35.3%. Operating cash flow minus capital spending left $10.2M of free cash flow in fiscal 2025. At September 30, 2026 it held $55.6M in cash against $11.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Eton Pharmaceuticals, Inc.
- Net worth
- Eton Pharmaceuticals, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $86.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $80M (+104.9% year on year), with a net loss of $4.6M. Over the 12 months to September 30, 2026: revenue $141.1M, net income $49.9M.
- Cash flow
- In fiscal 2025 operations brought in $10.5M of cash; after $333K of capital spending, free cash flow was $10.2M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Eton Pharmaceuticals, Inc.'s next report is expected around March 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Eton Pharmaceuticals, Inc. does
Eton Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ETON.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $80M | -$4.6M | -$0.17 | $10.2M |
| 2024 | $39M | -$3.8M | -$0.15 | $943K |
| 2023 | $31.6M | -$936K | -$0.04 | $6.8M |
| 2022 | $21.3M | -$9M | -$0.36 | $4.8M |
| 2021 | $21.8M | -$2M | -$0.08 | -$4.7M |
| 2020 | $39K | -$28M | -$1.33 | -$22.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ETON ranks in Health care
Latest SEC filings
What Eton Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 158% to $57.9M versus the same quarter last year; diluted EPS $1.06 versus -$0.07.
- November 5, 2026
- November 5, 2026Other event 8-K
- November 2, 2026Other event 8-K
- October 14, 2026
- September 28, 2026Other event 8-K
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 99% to $37.6M versus the same quarter last year; diluted EPS $0.35 versus -$0.10.
- August 13, 2026
- August 5, 2026
What is ETON worth? A DCF from its reported cash flow
Insider trades
What the people running Eton Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $10.9M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Krempa DavidChief Business Officer | Sold | 4,166 | $229.4K |
| October 2, 2026 | Krempa DavidChief Business Officer | Exercised options | 10,522 | - |
| August 28, 2026 | Maier Paul VDirector | Exercised options | 50,000 | $189K |
| August 28, 2026 | Maier Paul VDirector | Sold | 36,387 | $2.1M |
| August 28, 2026 | Maier Paul VDirector | Sold | 13,485 | $811.9K |
| August 28, 2026 | Maier Paul VDirector | Sold | 128 | $7.9K |
| August 28, 2026 | Maier Paul VDirector | Exercised options | 12,500 | $91.4K |
| August 24, 2026 | Krempa DavidChief Business Officer | Exercised options | 25,000 | $182.8K |
Who owns ETON
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Opaleye Management Inc.13G, passive with 2 related filers | 8.54% | November 6, 2026 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 7.7% | February 14, 2025 |
Largest institutional holders
Insiders
7 insiders reported holding 1,399,798 shares in total, about $90.1M at the last price.
| Holder | Shares |
|---|---|
| Brynjelsen SeanPresident & CEO, Director | 961,194 |
| Gruber James R.Chief Financial Officer | 213,420 |
| Maier Paul VDirector | 72,245 |
| Riedel Norbert GDirector | 67,155 |
| Krempa DavidChief Business Officer | 43,381 |
| Opaleye Management Inc.10% owner | 40,00040,000 held indirectly |
| Erdogan-Trinkaus IpekChief Commercial Officer | 2,403 |
Questions about ETON
What does Eton Pharmaceuticals, Inc. do?
Eton Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ETON. Its shares trade on NASDAQ under the ticker ETON.
What is Eton Pharmaceuticals, Inc.'s net worth?
Eton Pharmaceuticals, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $86.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Eton Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $49.9M on revenue of $141.1M, a net margin of 35.3%.
How much revenue does Eton Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Eton Pharmaceuticals, Inc. reported revenue of $141.1M. That is 100.6% more than a year earlier.
When did Eton Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Eton Pharmaceuticals, Inc.'s next earnings report?
Eton Pharmaceuticals, Inc.'s next report is expected around March 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ETON with
Follow ETON
Get an email when Eton Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Eton Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.